Long-acting beta2agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the COPD market, and both LAMAs and LABA/inhaled corticosteroid (ICS) FDCs are threatened by the uptake of these therapies. Additionally, generic versions of key market-leading therapies are becoming available, shifting prescribing patterns. Because of the progressive and irreversible nature of COPD, many patients are eventually prescribed a combination of a LABA, a LAMA, and an ICS, giving the first triple-therapy combination in its class, Trelegy, a promising market position.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed COPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed COPD patients?
- How has Trelegy been integrated into the treatment algorithm, and what is its source of business?
- What percentage of COPD patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of COPD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
- Chronic Obstructive Pulmonary Disease - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis
- Treatment Algorithms Chronic Obstructive Pulmonary Disease US April 2020
Author(s): Kristine Mackin, PhD
Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.
She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.